TXNDC9 knockdown inhibits lung adenocarcinoma progression by targeting YWHAG

Wang,Jing; Pan,Xiaotao; Li,Jie; Zhao,Jin

doi:10.3892/mmr.2022.12719

TXNDC9 knockdown inhibits lung adenocarcinoma progression by targeting YWHAG

Authors:
- Jing Wang
- Xiaotao Pan
- Jie Li
- Jin Zhao
View Affiliations

Affiliations: Respiratory and Critical Care Medicine Department, The Second People's Hospital of Shaanxi Province, Xi'an, Shaanxi 710005, P.R. China, General Surgery Department, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi 710600, P.R. China, Radiotherapy Department, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi 710600, P.R. China
Published online on: April 27, 2022 https://doi.org/10.3892/mmr.2022.12719
Article Number: 203
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is the most common form of lung cancer and with the highest mortality rate. Therefore, the identification and development of effective methods for the treatment of LUAD is of great importance. The present study aimed to investigate the role of thioredoxin domain‑containing protein 9 (TXNDC9) and tyrosine 3‑monooxygenase/tryptophan 5‑monooxygenase activation protein γ (YWHAG; also known as 14‑3‑3γ) in the progression of LUAD. The expression of TXNDC9 and its association with the survival of patients with LUAD was analyzed using Encyclopedia of RNA Interactomes. Reverse transcription‑quantitative PCR and western blot analysis were used to detect TXNDC9 mRNA and protein expression levels, respectively, in in vitro studies. To investigate the role of TXNDC9 in the progression of LUAD, TXNDC9 was silenced using small interfering RNA transfection. Furthermore, the viability, proliferation, migration, invasiveness and apoptosis of TXNDC9‑silenced A549 cells were detected using Cell Counting Kit (CCK)‑8, colony formation, wound healing, Transwell and TUNEL assays, respectively. The association between TXNDC9 and YWHAG was analyzed using STRING and Gene Expression Profiling Interactive Analysis databases, as well as co‑immunoprecipitation assays. Subsequently, YWHAG was overexpressed to similarly determine effects of YWHAG on viability, proliferation, migration, invasiveness and apoptosis of A549 cells. TXNDC9 expression was markedly upregulated in lung cancer cells, particularly A549 cells, and silencing of TXNDC9 expression suppressed the viability of the lung cancer cells. The results also revealed that TXNDC9 silencing exerted inhibitory effects on the viability, proliferation, migration and invasiveness of A549 cells, whereas the apoptotic rate was increased. Similar to TXNDC9, YWHAG expression was also upregulated in the A549 cells. Furthermore, TXNDC9 was demonstrated to bind to YWHAG and was positively associated with YWHAG. YWHAG overexpression reversed the inhibitory effects of TXNDC9 silencing on LUAD, as evidenced by increased viability, proliferation, migration and invasiveness, and decreased apoptosis, of A549 cells. The present study demonstrated that the knockdown of TXNDC9 exerted suppressive effects on LUAD, whereas YWHAG overexpression reversed the inhibitory effects of TXNDC9 silencing on LUAD. Therefore, TXNDC9 silencing may exert protective effects against LUAD by targeting YWHAG.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI
3	Song Q, Shang J, Yang Z, Zhang L, Zhang C, Chen J and Wu X: Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 17:702019. View Article : Google Scholar : PubMed/NCBI
4	Travis WD: Lung cancer pathology: Current concepts. Clin Chest Med. 41:67–85. 2020. View Article : Google Scholar : PubMed/NCBI
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
6	Ma F, Hou L and Yang L: Txndc9 is required for meiotic maturation of mouse oocytes. Biomed Res Int. 2017:62658902017. View Article : Google Scholar : PubMed/NCBI
7	Kang CH, Park JH, Lee ES, Paeng SK, Chae HB, Hong JC and Lee SY: Redox-dependent structural modification of nucleoredoxin triggers defense responses against alternaria brassicicola in arabidopsis. Int J Mol Sci. 21:91962020. View Article : Google Scholar : PubMed/NCBI
8	Feng T, Zhao R, Sun F, Lu Q, Wang X, Hu J, Wang S, Gao L, Zhou Q, Xiong X, et al: TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression. Oncogene. 39:356–367. 2020. View Article : Google Scholar : PubMed/NCBI
9	Lu A, Wangpu X, Han D, Feng H, Zhao J, Ma J, Qu S, Chen X, Liu B and Zheng M: TXNDC9 expression in colorectal cancer cells and its influence on colorectal cancer prognosis. Cancer Invest. 30:721–726. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chen D, Zou J, Zhao Z, Tang X, Deng Z, Jia J and Liu S: TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network. Cell Death Dis. 9:11102018. View Article : Google Scholar : PubMed/NCBI
11	Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol. 16:162–172. 2006. View Article : Google Scholar : PubMed/NCBI
12	Cho E and Park JY: Emerging roles of 14-3-3γ in the brain disorder. BMB Rep. BMB Rep. 53:500–511. 2020. View Article : Google Scholar : PubMed/NCBI
13	Ni J, Wang J, Fu Y, Yan C, Zhu M, Jiang Y, Chen J, Ding Y, Fan X, Li G and Jin G: Functional genetic variants in centrosome-related genes CEP72 and YWHAG confer susceptibility to gastric cancer. Arch Toxicol. 94:2861–2872. 2020. View Article : Google Scholar : PubMed/NCBI
14	Kim JO, Kim SR, Lim KH, Kim JH, Ajjappala B, Lee HJ, Choi JI and Baek KH: Deubiquitinating enzyme USP37 regulating oncogenic function of 14-3-3γ. Oncotarget. 6:36551–36576. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang P, Deng Y and Fu X: MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 482:935–941. 2017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
18	She J, Yang P, Hong Q and Bai C: Lung cancer in China: Challenges and interventions. Chest. 143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
19	Zhang C, Zhang Z, Zhang G, Zhang Z, Luo Y, Wang F, Wang S, Che Y, Zeng Q, Sun N and He J: Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett. 479:31–41. 2020. View Article : Google Scholar : PubMed/NCBI
20	Xu J, Li T, Wu H and Xu T: Role of thioredoxin in lung disease. Pulm Pharmacol Ther. 25:154–162. 2012. View Article : Google Scholar : PubMed/NCBI
21	Fan J, Yu H, Lv Y and Yin L: Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients. Tumour Biol. 37:1949–1958. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zhou W, Fang C, Zhang L, Wang Q, Li D and Zhu D: Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma. Biochem Biophys Res Commun. 524:582–588. 2020. View Article : Google Scholar : PubMed/NCBI
23	Wu Y, Ye H, Peng B, Jiang H, Tang Q, Liu Y, Xi J and Chen S: MiR-643 functions as a potential tumor suppressor in gastric cancer by inhibiting cell proliferation and invasion via targeting TXNDC9. Ann Clin Lab Sci. 51:494–502. 2021.PubMed/NCBI
24	Garcia SA and Nagai MA: Transcriptional regulation of bidirectional gene pairs by 17-β-estradiol in MCF-7 breast cancer cells. Braz J Med Biol Res. 44:112–122. 2011. View Article : Google Scholar : PubMed/NCBI
25	Raungrut P, Wongkotsila A, Lirdprapamongkol K, Svasti J, Geater SL, Phukaoloun M, Suwiwat S and Thongsuksai P: Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 15:3513–3518. 2014. View Article : Google Scholar : PubMed/NCBI
26	Holmes TR, Al-Matouq J, Holmes M, Nicola L, Rudd JC, Lovas S and Hansen LA: Targeting 14-3-3ε-CDC25A interactions to trigger apoptotic cell death in skin cancer. Oncotarget. 11:3267–3278. 2020. View Article : Google Scholar : PubMed/NCBI
27	Hiraoka E, Mimae T, Ito M, Kadoya T, Miyata Y, Ito A and Okada M: Correction to: Breast cancer cell motility is promoted by 14-3-3γ. Breast Cancer. 26:5942019. View Article : Google Scholar : PubMed/NCBI
28	Qi W, Liu X, Chen W, Li Q and Martinez JD: Overexpression of 14-3-3gamma causes polyploidization in H322 lung cancer cells. Mol Carcinog. 46:847–856. 2007. View Article : Google Scholar : PubMed/NCBI
29	Qi W, Liu X, Qiao D and Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer. 113:359–363. 2005. View Article : Google Scholar : PubMed/NCBI